Key facts
- This page summarizes Luis Borges's Form 4 filing for Metagenomi, Inc. (MGX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Apr 2024, 20:59.
Luis Borges - 01 Apr 2024 Form 4 Insider Report for Metagenomi, Inc. (MGX)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- MGX
- Reported as of
- 01 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Apr 2024, 20:59:50 UTC
- Prior SEC filing
- 08 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew L. Wein, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Luis Borges filed Form 4 for Metagenomi, Inc. (MGX) on 03 Apr 2024.
Change
- Previous filing in this sequence was filed on 08 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MGX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +69,316
- Change %
- Price
- $0.000000
- Shares after
- 69,316
- Date
- 01 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MGX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +291,450
- Change %
- Price
- $0.000000
- Shares after
- 291,450
- Date
- 01 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 291,450
- Exercise price
- $10.82
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on September 5, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Footnote F2
25% of the shares subject to this option shall vest and become exercisable on August 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.